Portopulmonary hypertension overview: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Portopulmonary hypertension}} {{CMG}} ==Overview== Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH i..." |
Irfan Dotani (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Portopulmonary hypertension}} | {{Portopulmonary hypertension}} | ||
{{CMG}} | {{CMG}}; {{AE}} | ||
{{PleaseHelp}} | |||
==Overview== | ==Overview== | ||
Portopulmonary hypertension (PPH) is defined by the coexistence of portal and [[pulmonary hypertension]]. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from [[cirrhosis]]. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition.<ref>Kuo PC et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999;67(8):1087-1093</ref> Today, PPH is comorbid in 4-6% of those referred for a [[liver transplant]].<ref> Torregosa et al. Role of Doppler echos in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation 2001;71:572-574</ref><ref name=Tapper> Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.</ref> | Portopulmonary hypertension (PPH) is defined by the coexistence of portal and [[pulmonary hypertension]]. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from [[cirrhosis]]. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition.<ref>Kuo PC et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999;67(8):1087-1093</ref> Today, PPH is comorbid in 4-6% of those referred for a [[liver transplant]].<ref> Torregosa et al. Role of Doppler echos in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation 2001;71:572-574</ref><ref name=Tapper> Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.</ref> | ||
==Historical Perspective== | |||
==Classification== | |||
==Pathophysiology== | |||
==Causes== | |||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | |||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications, and Prognosis== | |||
===Natural History=== | |||
===Complications=== | |||
===Prognosis=== | |||
==Diagnosis== | |||
===Diagnostic Criteria=== | |||
===History and Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | |||
===Medical Therapy=== | |||
===Surgery=== | |||
===Prevention=== | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
{{WS}} | |||
{{WH}} | |||
Latest revision as of 18:35, 18 July 2016
|
Portopulmonary hypertension Microchapters |
|
Differentiating Portopulmonary hypertension from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Portopulmonary hypertension overview On the Web |
|
American Roentgen Ray Society Images of Portopulmonary hypertension overview |
|
Directions to Hospitals Treating Portopulmonary hypertension |
|
Risk calculators and risk factors for Portopulmonary hypertension overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition.[1] Today, PPH is comorbid in 4-6% of those referred for a liver transplant.[2][3]
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Portopulmonary hypertension overview from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ Kuo PC et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999;67(8):1087-1093
- ↑ Torregosa et al. Role of Doppler echos in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation 2001;71:572-574
- ↑ Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.